Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to answer the following question: What are the effects of a new drug
or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue
for biomarkers to determine participation in the study.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
AstraZeneca BioAlta Cancer Research Institute, New York City